

Regulatory Story

[Go to market news section](#)



Omega Diagnostics Group PLC - ODX VISITECT® CD4 CE-Mark
Released 07:00 29-Nov-2017



RNS Number : 7714X
Omega Diagnostics Group PLC
29 November 2017

Omega Diagnostics Group PLC ("Omega" or the "Company")

VISITECT® CD4 CE-Mark

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has CE-Marked its VISITECT® CD4 test for helping to manage people living with HIV, following successful performance evaluations in India and the UK.

The successful completion of the CE-Mark process means these tests, which indicate whether a person's CD4 count is higher or lower than 350 cells/mm³, are available for general sale through business to business channels in countries not requiring individual product registration. The technical file forms the basis of the additional regulatory approval the Company will seek through the World Health Organisation Prequalification programme which assesses *in vitro* diagnostics tests for priority diseases and their suitability for use in resource-limited settings. A successful completion of this process will enable Omega to become eligible for public sector procurement. The Company anticipates that this process is likely to be completed during the second half of the next financial year.

In addition, the Company is looking to expand its VISITECT® product portfolio and is working on an additional version of the VISITECT® CD4 test which utilises a 200 cells/ mm³ cut-off. Recent global health guidelines confirm an opportunity also exists for a test that can indicate advanced HIV disease (a CD4 cell count which is lower than 200 cells/mm³) and the Company is working to ensure it has a product portfolio encompassing both existing and new opportunities.

Andrew Shepherd, Chief Executive Officer of Omega, commented: *"We are pleased to have achieved this major milestone and whilst the early opportunities are likely to lead to modest sales during the next twelve months, we anticipate generating significant demand once we*

have completed all the regulatory hurdles. We look forward to providing the global health community with unique point-of-care tests which address a significant unmet need."

Contacts:

Omega Diagnostics Group PLC

Andrew Shepherd, Chief Executive
Kieron Harbinson, Group Finance Director
Jag Grewal, Group Sales and Marketing Director

Tel: 01259 763 030

www.omegadiagnostics.com

finnCap Ltd

Geoff Nash/James Thompson (Corporate Finance)
Mia Gardner (Corporate Broking)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or

omega@walbrookpr.com

Mob: 07980 541 893

Mob: 07584 391 303

This information is provided by RNS
The company news service from the London Stock Exchange

END

RESUWVNRBUAAUAA

CLOSE

Sponsored Business Content

dianomi™

- **3 Shares With Potential To Beat Brexit Uncertainty**
Hargreaves Lansdown
- **Get the outlook for the coming months from global fund managers**
Russell Investments
- **Aberdeen Frontier Markets: Diversified access to up-and-coming markets**
Aberdeen Investment Trusts
- **Beyond the election: why we must keep the long-term view in sight**
BlackRock

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. **Terms and conditions**, including restrictions on use and distribution apply.

VISITECT® CD4 CE-Mark - RNS